Well Honeycomb, this is a reason for the December 5th micro investor conference. Perhaps, the tide is changing for INNV and with some additional hard work, things will begin to fall into place with some capital to properly launch and market Fluticare.
Either way, I don't think these next two Q's are make it or break it for investors or INNV. These 2 Q's are a major indicator of course, but if it doesn't turn out ultra positive in INNV's favor...
I think it means it will just take longer for INNV to achieve it's goal of being the largest over the counter provider of men and women's health care products.
I would imagine that Dr.Damaj, like other men is able to learn from his experience and improve as time goes on.
I understand the logic behind just wanting to mainly focus on Fluticare, especially if you think the goal for INNV was to be bought out.
However, I also like Dr.Damaj's idea of actually becoming the largest over the counter provider of men and women's health care products, which takes time and I am patient.
I'm sure we'd all like instant-ultra success, but I can wait for it and if the share price continues to drop, it will give me the opportunity to average down again.
In my opinion, at the December 5th micro investor conference, INNV is going to attract a good investor/backer and that INNV will be in much better, overall position in the summer/fall of 2018.
As a result, Fluticare will be launched in a better manner, but not as perfectly as Flonase, but Fluticare won't flop either.
I sort of like the way Damaj is slowly ramping up, since the original Fluiticare ANDA for world-wide sales has been delayed.
I see INN getting Fluticare in the USA off the ground, hiring more employees, launching more products, slowly growing and when the original Fluticare ANDA hits, being in a much better position to launch Fluticare world-wide.
